Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Fulgent Genetics Inc FLGT

Healthcare
Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Company’s laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services.


NDAQ:FLGT - Post by User

Fulgent Genetics Inc
<< Previous
 Bullboard Posts
User Avatar Image
(229)
•••
Post by whytestockson Aug 02, 2024 11:01am
28 Views
Post# 36160832

Fulgent Reports Second Quarter 2024 Financial Results&#xA0;

Fulgent Reports Second Quarter 2024 Financial Results&#xA0;
News; $FLGT Fulgent Reports Second Quarter 2024 Financial Results&#xA0;Total Revenue of $71.0 million Core Revenue grows 5% year-over-year to $70.2 million Reiterates Full Year 2024 Core Revenue Guidance of $280 million, Improves Earnings Per Share Guidance for 2024 Fulgent Genetics, Inc. (NASDAQ: FLGT) (&#x201C;Fulgent,&#x201D; or the &#x201C;Co...FLGT - Fulgent Reports Second Quarter 2024 Financial Results&#xA0;

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities